EGFR and squamous cell carcinoma: On A431 squamous carcinoma cells that overexpress EGFR [21], we show that peripheral blood serum samples, which we took from seven healthy female donors, could antagonize the effects of EGFR-targeted drugs erlotinib and cetuximab by increasing their half-inhibitory concentrations by about 2- and 20-fold, respectively.